Cm. D'Cruz et al., c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations, NAT MED, 7(2), 2001, pp. 235-239
Citations number
24
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research General Topics
Although the process of mammary tumorigenesis requires multiple genetic eve
nts, it is unclear to what extent carcinogenesis proceeds through preferred
secondary pathways following a specific initiating oncogenic event. Simila
rly, the extent to which established mammary tumors remain dependent on ind
ividual mutations for maintenance of the transformed state is unknown. Here
we use the tetracycline regulatory system to conditionally express the hum
an c-MYC oncogene in the mammary epithelium of transgenic mice. MYC encodes
a transcription factor implicated in multiple human cancers. In particular
, amplification and overexpression of c-MYC in human breast cancers is asso
ciated with poor prognosis, although the genetic mechanisms by which c-MYC
promotes tumor progression are poorly understood(1,2). We show that deregul
ated c-MYC expression in this inducible system results in the formation of
invasive mammary adenocarcinomas, many of which fully regress following c-M
YC deinduction. Approximately half of these tumors harbor spontaneous activ
ating point mutations in the ros family of proto-oncogenes with a strong pr
eference for Kras2 compared with Hras1. Nearly all tumors lacking activatin
g ras mutations fully regressed following c-MYC deinduction, whereas tumors
bearing ras mutations did not, suggesting that secondary mutations in ras
contribute to tumor progression. These findings demonstrate that c-MYC-indu
ced mammary tumorigenesis proceeds through a preferred secondary oncogenic
pathway involving Kras2.